drugset / Trial / NCT00857584

Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy

NCT00857584

Phase 3 Completed 27 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

Prospective, open-label, controlled (active comparator), randomized study of 8 weeks follow-up for the evaluation of the efficacy of extended release quetiapine (quetiapine XR) versus Sertraline in addition to previous mood stabilizer treatment (lithium or valproate at stable and clinically therapeutic blood levels) in the treatment of the adult bipolar depression. This multicentric study will be featured in two sites in Spain.

Timeline

Start
2009-05
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 300 mg Oral
Subject Quetiapine Small molecule 600 mg Oral
Comparator Sertraline Small molecule 50 mg Oral
Comparator Sertraline Small molecule 200 mg Oral
Background Lithium Unknown
Background Valproate Small molecule

Indications